In vivo 5-HT 6 receptor occupancy by antipsychotic drugs in the rat brain

Neuroscience Letters

Volumn 503, Issue 3, 2011, Pages 240-243

  Hirano, Kazufumi ^a   Searle, Kirsten L ^a   Nasir, Shabina ^a   Aw, Chiu Cheong ^a   Browne, Edward R ^a   Rutter, A Richard ^a  

^a Neural Pathway Discovery Performance Unit   (Singapore)

Author keywords

5 HT 6; 3H GSK215083; Antipsychotic drug; Chlorpromazine; Clozapine; In vivo binding; Olanzapine

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; OLANZAPINE; RADIOLIGAND; SEROTONIN 6 RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BRAIN LEVEL; DRUG RECEPTOR BINDING; IN VIVO STUDY; LIGAND BINDING; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOASSAY; RAT; RECEPTOR OCCUPANCY;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRAIN; CHLORPROMAZINE; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; PIPERAZINES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN; SULFONAMIDES;

EID: 80053253570     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.08.044     Document Type: Article

References (39)

1. Bilder R.M., Goldman R.S., Robinson D., Reiter G., Bell L., Bates J.A., Pappadopulos E., Willson D.F., Alvir J.M., Woerner M.G., Geisler S., Kane J.M., Lieberman J.A. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am. J. Psychiatry 2000, 157:549-559.
2. Chung Y.C., Lee C.R., Park T.W., Yang K.H., Kim K.W. Effect of donepezil added to atypical antipsychotics on cognition in patients with schizophrenia: an open-label trial. World J. Biol. Psychiatry 2009, 10:156-162.
3. 6 receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacology 2001, 25:662-668.
4. 6 receptors: a comparative study of coupling to Gαs. Eur. J. Pharmacol. 2008, 588:170-177.
5. 6 receptor antagonist SB-271046 reverses scopolamine-disrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats. Neuropsychopharmacology 2004, 29:93-100.
6. 6 receptor in cognitive function. Neuropharmacology 2008, 55:1015-1022.
7. Fuller R., Nopoulos P., Arndt S., O'Leary D., Ho B.C., Andreasen N.C. Longitudinal assessment of premorbid cognitive functioning in patients with schizophrenia through examination of standardized scholastic test performance. Am. J. Psychiatry 2004, 161:580-581.
8. Garzya V., Forbes I.T., Gribble A.D., Hadley M.S., Lightfoot A.P., Payne A.H., Smith A.B., Douglas S.E., Cooper D.G., Stansfield I.G., Meeson M., Dodds E.E., Jones D.N., Wood M., Reavill C., Scorer C.A., Worby A., Riley G., Eddershaw P., Ioannou C., Donati D., Hagan J.J., Ratti E.A. Studies towards the identification of a new generation of atypical antipsychotic agents. Bioorg. Med. Chem. Lett. 2007, 17:400-405.
9. 6 receptor-like material in the rat central nervous system. Brain Res. 1997, 746:207-219.
10. 6 receptor mRNA in the central nervous system of control or 5,7-dihydroxytryptamine-treated rats. Synapse 1996, 23:164-173.
11. 6 serotonin receptors may reflect psychoactive profile. Mol. Med. 1995, 1:398-406.
12. Heinrichs R.W., Zakzanis K.K. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998, 12:426-445.
13. Hirst W.D., Abrahamsen B., Blaney F.E., Calver A.R., Aloj L., Price G.W., Medhurst A.D. Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling. Mol. Pharmacol. 2003, 64:1295-1308.
14. 6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur. J. Pharmacol. 2006, 553:109-119.
15. A.J. Hunter, Neurology CEDD. Focus on Alzheimer's disease, GlaxoSmithKline, 2007. http://www.gsk.com/investors/presentations/2007/neurosciences-seminar-dec07/jackie-hunter.pdf.
16. Kapur S., Barlow K., VanderSpek S.C., Javanmard M., Nobrega J.N. Drug-induced receptor occupancy: substantial differences in measurements made in vivo vs ex vivo. Psychopharmacology (Berl.) 2001, 157:168-171.
17. 3H]M100907 binding assay to determine a translatable measure of 5-HT(2A) receptor occupancy. Eur. J. Pharmacol. 2008, 591:136-141.
18. A receptors. Neuropharmacology 2006, 51:168-172.
19. 6 PET radioligand in the porcine brain. J. Label. Compd. Radiopharm. 2005, 48:S7.
20. Mauri M.C., Volonteri L.S., Colasanti A., Fiorentini A., De Gaspari I.F., Bareggi S.R. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin. Pharmacokinet. 2007, 46:359-388.
21. 6 receptors: a novel target for cognitive enhancement. Pharmacol. Ther. 2005, 108:320-333.
22. Millan M.J., Marin P., Bockaert J., la Cour C.M. Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions. Trends Pharmacol. Sci. 2008, 29:454-464.
23. Miller D.D., Fleming F., Holman T.L., Perry P.J. Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J. Clin. Psychiatry 1994, 55(Suppl. B):117-121.
24. Potkin S.G., Bera R., Gulasekaram B., Costa J., Hayes S., Jin Y., Richmond G., Carreon D., Sitanggan K., Gerber B. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J. Clin. Psychiatry 1994, 55(Suppl. B):133-136.
25. 6 receptor antagonists. Curr. Opin. Investig. Drugs 2001, 2:104-109.
26. 6 receptor antagonist. J. Med. Chem. 2003, 46:1273-1276.
27. 6 receptor antagonists enhance retention of a water maze task in the rat. Psychopharmacology (Berl.) 2001, 158:114-119.
28. Roth B.L., Craigo S.C., Choudhary M.S., Uluer A., Monsma F.J., Shen Y., Meltzer H.Y., Sibley D.R. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J. Pharmacol. Exp. Ther. 1994, 268:1403-1410.
29. 6 receptor antagonist RO4368554 in rat models for cognition and sensorimotor gating. Eur. Neuropsychopharmacol. 2007, 17:277-288.
30. Schotte A., Janssen P.F., Megens A.A., Leysen J.E. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res. 1993, 631:191-202.
31. Shirazi-Southall S., Rodriguez D.E., Nomikos G.G. Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology 2002, 26:583-594.
32. 2 receptor occupancy. Neuropsychopharmacology 1995, 12:57-64.
33. 2 receptors. J. Pharmacol. Exp. Ther. 1993, 266:1374-1384.
34. Uchida S., Kato Y., Hirano K., Kagawa Y., Yamada S. Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. Life Sci. 2007, 80:1635-1640.
35. Ward R.P., Hamblin M.W., Lachowicz J.E., Hoffman B.J., Sibley D.R., Dorsa D.M. Localization of serotonin subtype 6 receptor messenger RNA in the rat brain by in situ hybridization histochemistry. Neuroscience 1995, 64:1105-1111.
36. Wilkinson D.G. The pharmacology of donepezil: a new treatment of Alzheimer's disease. Expert Opin. Pharmacother. 1999, 1:121-135.
37. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 2005, 8:457-472.
38. 6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology 2001, 41:210-219.
39. Woolley M.L., Marsden C.A., Fone K.C. 5-ht6 receptors. Curr. Drug. Targets CNS Neurol. Disord. 2004, 3:59-79.